Phathom Pharmaceuticals
PHAT· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +104.3% in FY2025
Steven Basta is the CEO of Phathom Pharmaceuticals and was paid $7.0M in FY2025 (Dec).
Pay$100 in the stock at the end of FY24 → $204
Executives5
See all- 1Steven BastaPresident and Chief Executive OfficerFY2025
- 2Terrie CurranFormer President and Chief Executive OfficerFY2025
- 3Sanjeev NarulaChief Financial and Business OfficerFY2025
- 4Azmi Nabulsi, M.D., M.P.H.Former Chief Operating OfficerFY2025
- 5Anne Marie CookChief Legal Officer and SecretaryFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allPhathom Pharmaceuticals paid its 5 named executives $20.3M in total in FY2025 (Dec). CEO Steven Basta was paid $7.0M of that.
| Name | |||
|---|---|---|---|
| Steven BastaPresident and Chief Executive Officer | Not disclosed | Not disclosed | |
| Terrie CurranFormer President and Chief Executive Officer | |||
| Sanjeev NarulaChief Financial and Business Officer | Not disclosed | Not disclosed | |
| Azmi Nabulsi, M.D., M.P.H.Former Chief Operating Officer | |||
| Anne Marie CookChief Legal Officer and Secretary | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Phathom Pharmaceuticals. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board1
See all- Mark StenhouseDirector · 4 yr on the boardIndependentCompensation—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 7, 2026 | FY2025 |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 23, 2025 | FY2024 |
| Annual report | 10-K | Mar 6, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 12, 2024 | FY2023 |
| Annual report | 10-K | Mar 7, 2024 | FY2023 |
